Author’s response to reviews

Title: Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: A case report

Authors:
Jianping Lai (yipingqingyun@163.com)
Peng Xu (512073602@qq.com)
Xiaoliu Jiang (923165950@qq.com)
Shan Zhou (259324509@qq.com)
Anwen Liu (awliu666@163.com)

Version: 1 Date: 04 May 2017

Author’s response to reviews:

Dear Editors and Reviewers,

Thank you for your letter and for the reviewers’ comments concerning our manuscript entitled “Successful anti-PD-1 antibody treatment in a relapsed NK/T lymphoma patient with resistance to multi-line treatment: a case report”. (BCAN-D-17-00424). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer’s comments are as flowing:

Responds to the reviewer’s comments:

Reviewer #1 (Enrico Derenzini):

1. Response to comment: (radiologic findings and PET/CT images before and after pembrolizumab therapy are not provided)

Response: Considering the Reviewer’s suggestion, Line 1-2, page 7 and line 9-11, page 7 were added.
2. Response to comment: (With these premises, the author should provide much more details on treatment evaluation of perhaps molecular monitoring of the disease during treatment.)

Response: We have made correction according to the Reviewer’s comments. Line 8-13, page 2 and line 7-9, page 7 were added.

Reviewer #2 (Debmalya Bhattacharyya):

1. Response to comment: (Several acronyms need to properly explained Such as ENKTL, ORR etc.)

Response: We are very sorry for our negligence of explanation of some abbreviations. “ENKTL” were corrected as “NKTCL”. PD-1, EBV, CR, ORR, OS, DFS, PFS were explained in the abbreviations.

2. Response to comment: (The authors need to highlight the significance of the case study and how it stands out, and compare to that of previous studies.)

Response: Line 14-19, page 10 were re-written according to the Reviewer’s suggestion.

3. Response to comment: (Furthermore, the authors do not mention if there was any side effects of the treatment.)

Response: Considering the Reviewer’s suggestion, line 12-17, page 7 were added.

Reviewer #3 (Amit Singh):

1. Response to comment: (English language within manuscript should be improved)

Response: manuscript were reviewed by someone who is fluent in English.

Special thanks to you for your good comments.

We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. And here we list the changes and marked in red in revised paper. We appreciate for Editors/Reviewers’ warm work earnestly, and hope that the correction will meet with approval.

Once again, thank you very much for your comments and suggestions.
Yours sincerely,

Jianping Lai

Corresponding author:

Name: Anwen Liu

E-mail: awliu666@163.com